Sanofi/€SAN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
- Ticker
- €SAN
- Sector
- Health
- Primary listing
- PAR
- Employees
- 74,846
- Headquarters
- Paris, France
- Website
- www.sanofi.com
Sanofi Metrics
BasicAdvanced
€89B
22.82
€3.26
0.28
€4.12
5.53%
Price and volume
Market cap
€89B
Beta
0.28
52-week high
€90.90
52-week low
€71.25
Average daily volume
2.3M
Dividend rate
€4.12
Financial strength
Current ratio
0.987
Quick ratio
0.214
Long term debt to equity
0.235
Total debt to equity
0.339
Dividend payout ratio (TTM)
124.38%
Interest coverage (TTM)
16.22%
Profitability
EBITDA (TTM)
13,657
Gross margin (TTM)
73.45%
Net profit margin (TTM)
8.09%
Operating margin (TTM)
21.16%
Effective tax rate (TTM)
23.16%
Revenue per employee (TTM)
€650,000
Management effectiveness
Return on assets (TTM)
5.09%
Return on equity (TTM)
5.71%
Valuation
Price to earnings (TTM)
22.817
Price to revenue (TTM)
1.839
Price to book
1.28
Price to tangible book (TTM)
99.21
Price to free cash flow (TTM)
10.389
Free cash flow yield (TTM)
9.63%
Free cash flow per share (TTM)
7.168
Dividend yield (TTM)
5.53%
Forward dividend yield
5.53%
Growth
Revenue change (TTM)
6.95%
Earnings per share change (TTM)
-55.68%
3-year revenue growth (CAGR)
2.04%
10-year revenue growth (CAGR)
3.67%
3-year earnings per share growth (CAGR)
-21.90%
10-year earnings per share growth (CAGR)
0.16%
3-year dividend per share growth (CAGR)
4.99%
10-year dividend per share growth (CAGR)
3.47%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Analyst projections of the future price of Sanofi stock.
Bulls say / Bears say
Dupixent still has powerful momentum: Q2 sales rose 37.6% to €5.2bn, and Sanofi now targets about €25bn in annual sales by 2030. This gives earnings a strong near-term growth engine. (Sanofi)
Sales from newer pharma launches climbed 48.3% to €1.3bn in Q2, led by Ayvakit, ALTUVIIIO and Sarclisa. Sanofi also raised its 2026 sales-growth outlook to around 10%, suggesting growth is beginning to broaden beyond its biggest drug. (Sanofi)
EU approval of Cenrifki gives Sanofi a first-in-class treatment for non-relapsing secondary progressive multiple sclerosis, with Phase 3 data showing delayed disability progression. It adds a new commercial opportunity beyond the immunology blockbuster. (Sanofi)
The pipeline remains an execution risk: Sanofi stopped amlitelimab development in atopic dermatitis and discontinued itepekimab and balinatunfib programmes, alongside a €952m impairment linked to amlitelimab. That leaves fewer candidates to help replace future blockbuster revenue. (Reuters)
Sanofi’s reliance on Dupixent makes its approaching patent cliff increasingly important: the drug brought in €17.8bn in 2025, with patent protection expected to expire in 2031. If replacement products disappoint, the company faces a substantial revenue gap. (BioPharma Dive, Reuters)
Q2’s 17.8% sales growth may be hard to sustain: management expects growth to normalise in the second half, while vaccine sales already fell 4.7% year on year. That raises the risk of a marked slowdown from the latest quarter. (Sanofi)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Sanofi
AllEURUSDGBP
Fund name | Fund size | €SAN weighting |
|---|---|---|
Amundi CAC 40€C40 | €999M | 6.03% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 4.87% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 4.87% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 4.75% |
iShares Edge MSCI Europe Value Factor£IEFV | €2.6B | 4.28% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.